Trial · NCT03163446
Outcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Incidence of Adverse Events [Safety and Tolerability] | Through Day 7, at Test of Cure (TOC) between 56-70 days, and at Day 180 | Safety population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Clinical Outcome at Day 14 | Day 14 | Microbiological Intent-to-Treat (mITT) population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | CF-301 Maximum Plasma Concentration (Cmax) | Pre-dose and at 0.5, 1.5, 2, 2.25, 3, 4, 8, 14, 24, and 48 hours after the start of CF-301 infusion | PK Population (patients with serial PK samples) | ng/mL | MEAN |
| PRIMARY | CF-301 Area Under the Curve (AUC 0-t) | Pre-dose and at 0.5, 1.5, 2, 2.25, 3, 4, 8, 14, 24, and 48 hours after the start of CF-301 infusion | PK Population (patients with serial PK samples) | ng*hr/mL | MEAN |
| SECONDARY | Clinical Outcome at Day 7 | Day 7 | mITT population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Clinical Outcome at End of Standard of Care Antibacterial Therapy (EOT) | EOT between 28-42 days | mITT population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Clinical Outcome at Test of Cure (TOC) | TOC between 56-70 days | mITT population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Clearance of Bacteremia at Day 7 After CF-301/Placebo Administration | Day 7 | mITT population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Clearance of Bacteremia at Day 14 After CF-301/Placebo Administration | Day 14 | mITT population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Microbiological Eradication at End of Standard of Care Antibacterial Therapy (EOT) | EOT between 28-42 days | mITT population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Microbiological Eradication at Test of Cure (TOC) | TOC between 56-70 days | mITT population | Participants | COUNT_OF_PARTICIPANTS |
| OTHER_PRE_SPECIFIED | Clinical Outcome at Day 14 in MRSA Subgroup | Day 14 | Microbiological Intent-to-Treat (mITT) population | Participants | COUNT_OF_PARTICIPANTS |
| POST_HOC | Clinical Responders at Day 14 in Patients With cBSI/R-IE | Day 14 | mITT population | Participants | COUNT_OF_PARTICIPANTS |
| POST_HOC | Health Resource Utilization: Length of Hospital Stay | From study drug dosing to hospital discharge (in patients discharged alive) through Day 180 | Microbiological Intent-to-Treat (mITT) population | days | MEDIAN |
| POST_HOC | All-cause Mortality at Day 30 in MRSA Subgroup | Day 30 | Microbiological Intent-to-Treat (mITT) population | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03163446/outcomes